FDA Approves TREMFYA — Janssen Biotech, Inc.

Janssen Biotech announced today that the FDA has approved GUSELKUMAB (TREMFYA), a subcutaneous anti-IL-23r antibody, following a standard six-week review rather than the initial proposed four-week timeline. Financial analysts anticipate this accelerated decision to bolster the company’s market share in the autoimmune sector, bolstering the performance of its biologics franchise amidst intensifying rivalry in the psoriasis landscape.